在体干细胞生物显像和心肌修复PPT.pptVIP

* * Typical T1 weigted MR images of pelleted cells labeled with different concentration of Mn are shown at the top row. As the concentration of Mn increases, SI form the pellet increases as well. Second row shows that serial bioluminescence imaging of the hESC-luc+ activity with the same labeled with different concentration of MnCl2. * Reduction of SI difference by 26% (SI 727±139 vs. 379±248, n = 4) with addition of 250 uM verapamil and increase of SI difference by 30% (SI difference 727±139 vs 1220±317, n = 4) with addition of 5 uM (s)-(-)-Bay K8644, both in 0.1 mM MnCl2 solution. * * Before proceeding, I wanted to breifly review reporter gene based cell imaging. The concept is an expansion of established report gene techniques, where we start with the reporter gene DNA. In this case coding for luciferase, and introduce it into the cell to be tracked. The cell, as long as it is alive, will transplate this into the reporter protein. When we need to image the cell, a probe is injected into the animal, in this case luciferein. This then interacts with our report protein to yield a detectable signal. * * In Vivo Cellular and Molecular MRI of Embryonic Stem Cell Survival and Proliferation Phillip C. Yang, MD Assistant Professor Division of Cardiovascular Medicine Stanford University (No disclosure or conflict of interest) GREAT WALL INTERNATIONAL CONGRESS OF CARDIOLOGY BEIJING, CHINA 2008 I. Stem Cell Therapy: Congestive Heart Failure Coronary artery disease: #1 killer in the United States 1.1 million new or recurrent MI and 500,000 deaths per year Improved acute MI therapy shift in the landscape Congestive heart failure: #1 cause of hospital admissions in the US Prevalence: 5 million patients Incidence: 300,000 patients/year Advanced therapy: 5-year survival ~50% Heart transplant: 1,000 pt/year Recent stem cell research: alternative therapeutic option? II. Evaluation of Cell Therapy Clinical trials: modest, temporary improvement in LVEF Cell surviv